ABOS Stock Overview
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer’s disease.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Acumen Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.13 |
| 52 Week High | US$11.31 |
| 52 Week Low | US$1.81 |
| Beta | 0.082 |
| 1 Month Change | -27.21% |
| 3 Month Change | -3.10% |
| 1 Year Change | -14.48% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -84.43% |
Recent News & Updates
Recent updates
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
Sep 28Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
Jun 30We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Jan 07Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 01Shareholder Returns
| ABOS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.6% | -2.5% | -3.2% |
| 1Y | -14.5% | -3.7% | 19.3% |
Return vs Industry: ABOS underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: ABOS underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| ABOS volatility | |
|---|---|
| ABOS Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ABOS's share price has been volatile over the past 3 months.
Volatility Over Time: ABOS's weekly volatility has decreased from 15% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 52 | Dan O'Connell | acumenpharm.com |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Acumen Pharmaceuticals, Inc. Fundamentals Summary
| ABOS fundamental statistics | |
|---|---|
| Market cap | US$188.05m |
| Earnings (TTM) | -US$52.37m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.6x
P/E RatioIs ABOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABOS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$42.32m |
| Gross Profit | -US$42.32m |
| Other Expenses | US$10.05m |
| Earnings | -US$52.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 11.2% |
How did ABOS perform over the long term?
See historical performance and comparison